Peregrine Pharmaceuticals reported $203.49M in Current Assets for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US $ 290.48M 41.49M
Amgen AMGN:US $ 18520M 865M
AstraZeneca AZN:LN 22.65B 3.6B
Biocryst Pharmaceuticals BCRX:US $ 511.71M 54.42M
Bristol Myers Squibb BMY:US $ 30121M 3141M
Celldex Therapeutics CLDX:US $ 390.7M 20.14M
Chemocentryx CCXI:US $ 351.63M 82.46M
Eli Lilly And LLY:US $ 16964.7M 1487.7M
GlaxoSmithKline GSK:LN 28.99B 10.31B
Immunogen IMGN:US $ 456.72M 43.28M
Intrexon XON:US $ 154.94M 1.69M
Karyopharm Therapeutics KPTI:US $ 276.53M 927K
Macrogenics MGNX:US $ 218.2M 61.36M
Mannkind MNKD:US $ 184.26M 35.48M
Merk MRK:US $ 31184M 918M
Minerva Neurosciences NERV:US $ 55.7M 6.5M
Newlink Genetics NLNK:US 92.64M 7.03M
Novartis NOVN:VX 37.24B 8.48B
Novavax NVAX:US $ 2347.41M 192.29M
Peregrine Pharmaceuticals PPHM:US $ 203.49M 3.43M
Repligen RGEN:US $ 944.79M 13.11M
Xencor XNCR:US $ 505.97M 81.6M